OnKure Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +35.1% | +674.0% | +44.7% | +18.2% | +25.4% | |
| – | – | – | +314.6% | +2,176.4% | +156.8% | |
| – | -644.7% | – | -99.7% | -65,966.7% | – | |
| – | +725.0% | +472.7% | -78.3% | -78.9% | -11.5% | |
| – | -416.9% | -95.1% | -78.3% | – | -100.3% | |
| – | – | – | – | – | -100.0% | |
| – | +180.1% | -80.0% | +100.7% | +118.6% | -99.9% | |
| – | +96.7% | -102.3% | – | +341.2% | -163.9% | |
| – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.